Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Institutional and Insider Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 28.5% of Compass Therapeutics shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Compass Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | N/A | N/A | -$42.49 million | ($0.37) | -9.46 |
| Cardiff Oncology | $490,000.00 | 469.56 | -$41.44 million | ($0.94) | -4.79 |
Cardiff Oncology has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Compass Therapeutics and Cardiff Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 0 | 2 | 4 | 0 | 2.67 |
| Cardiff Oncology | 0 | 0 | 3 | 0 | 3.00 |
Compass Therapeutics presently has a consensus target price of $11.80, indicating a potential upside of 237.14%. Cardiff Oncology has a consensus target price of $10.33, indicating a potential upside of 129.63%. Given Compass Therapeutics’ higher probable upside, equities analysts plainly believe Compass Therapeutics is more favorable than Cardiff Oncology.
Profitability
This table compares Compass Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -32.37% | -30.67% |
| Cardiff Oncology | -6,238.17% | -73.97% | -60.40% |
Summary
Compass Therapeutics beats Cardiff Oncology on 8 of the 12 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
